Mergers & Acquisitions ·
Cumberland shareholders approve $375M deal to integrate commercial products with Apotex affiliate
CPIXCumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc. shareholders approved a strategic transaction to integrate its commercial products with the U.S. branded business of an Apotex Inc. affiliate, as outlined in an Asset Purchase Agreement dated April 22, 2026. The proposal received 99.84% approval from votes in favor, with 10,492,455 votes in favor out of 10,509,626 present. Cumberland Pharmaceuticals Inc. is a pharmaceutical company that manages FDA-approved commercial products.